Role of disorders related to idiotypic and anti-idiotypic interactions in slowing down the achievement of negative serologic reactions in patients with early onset forms of syphilis after specific therapy

Cover Page

Cite item


Goal. To study the humoral immunity state in patients with the slowed down achievement of negative serologic reactions after the treatment of early onset forms of syphilis by means of examining the blood serum level of idiotypic and anti-idiotypic antibodies to cardiolipin and p17 Treponema Pallidum antigenic protein. Materials and methods. The study involved 324 patients (39.5% male and 60.5% female) with the slowed down achievement of negative serologic reactions. Primary (idiotypic) antibodies to cardiolipin and p17 protein were obtained using immunochromatographic assays with the help of the Bio Logik LP system. Purified antibodies were concentrated using the ultrafiltration technique with the aid of the XM-100А membrane. To obtain the rabbit antiserum to p17 Treponema Pallidum protein, chinchilla rabbits were immunized using the commercial recombinant p17 protein. To determine anti-cardiolipin idiotypic antibodies in the blood serum, the ELISa method optimized for detecting anti-cardiolipin antibodies was applied. To determine anti-cardiolipin anti-idiotypic antibodies as well as idiotypic and anti-idiotypic antibodies to p17 Treponema Pallidum protein, the standard ELISA method was applied. The following antigens were used to process the pads: F(ab)2 fragments of anti-cardiolipin antibodies (5 μg/mL), recombinant р17 T. pallidum protein (5 μg/mL) and F(ab)2 fragments of antibodies to р17 T. pallidum protein (10 μg/mL). The level of antibodies was assessed based on the absorbancy and expressed in conventional activity units using the K coefficient being the absorbancy of the serum under examination to the mean absorbancy of control serums ratio. The K value exceeding 1.5 conventional units indicated the increased level of antibodies. Results. Patients with the slowed down achievement of negative serologic reactions demonstrated a selective increase in the level of anti-idiotypic antibodies (AIAB) relative to T. pallidum antigens, cardiolipin and p17 protein, vs. first-order antibodies, which points at abnormal mutual regulation between idiotypic antibodies (IAB) and AIAB; the discovered phenomenon lays the immunochemical basis for the formation of a self-sustaining “vicious circle” contributing to the induction of high levels of antibodies to treponema antigens even when the pathogen was destroyed.

About the authors

YE. N. Volkova

The Russian National Research Medical University named after N.I. Pirogov (RNRMU)

Author for correspondence.
Russian Federation

S. G. Morozov

Federal State Budgetary Institution «Institute of General Pathology and Pathophysiology» under the Russian Academy of Medical Sciences

Russian Federation

YE. V. Mitichkina

Central Military Clinical Hospital Russian Interior Troops

Russian Federation

A. A. Grigoriyeva

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Russian Federation

I. V. Yelistratova

Central Military Clinical Hospital Russian Interior Troops

Russian Federation


  1. Прохоренков В.И., Аковбян В.А. Серорезистентность после проведенного лечения сифилиса: болезнь или состояние. Consilium medicum 2002; 4 (5): 152-154.
  2. Лосева О.К., Катунин Г.Л. Скрытый сифилис и серорезистентность. Вестн. дерматол. и венерол. 2004; (5): 42-43.
  3. Чеботарев В.В., Чеботарева Н.В., Павлик Л.В. Серорезистентность: «явление» при сифилисе. Росс. журн. кож. и вен. бол. 2006; (2): 30-33.
  4. Дмитриев А.Г., Афонин А.В. О возможной причине возникновения серорезистентности при сифилитической инфекции. Вестн. дерматол. и венерол. 2003; (2): 47-48.
  5. Вислобоков А.В. Факторы, способствующие возникновению серорезистентности. Росс. журн. кож. и вен. бол. 2005; (4): 20-23.
  6. Нестеренко В.Г., Аковбян В.А., Петренко Л.А. и др. Серорезистентность после лечения сифилиса: дюрантные пенициллины и новый серологический диагностический комплекс. Росс. журн. кож. и вен. бол. 2005; (4): 12-16.
  7. Чимитова И.А. Серорезистентный сифилис и обоснование применения цефтриаксона в лечении больных. Диссертация.. к.м.н. М; 2000.
  8. Li J., Wang L.N., Zuo Y.G. et al. Clinical analysis and study of immunological function in syphilis patients with seroresistance. Zhonghua Yi Xue Za Zhi 2009; 89 (12): 813-816.
  9. Wang L.N., Zuo Y.G., Liu Y.X. et al. Incidence of seroresistance of syphilis and its relevant factors. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2008; 30 (3): 338-341.
  10. Дмитриев Г.А., Фриго Н.В. Сифилис. Дифференциальный клинико-лабораторный диагноз. Москва: Медицинская книга; 2004.
  11. Миронов А.Ю., Терехова Ю.Б. Современные методы диагностики сифилиса. Consilium medicum Ukraina 2008; (6): 31-36.
  12. González-López J.J., Guerrero M.L., Luján R. et al. Factors determining serologic response to treatment in patients with syphilis. Clin Infect Dis 2009; 49 (10): 1505-1511.
  13. Nakatani K., Takeshita S., Tsujimoto H. et al. Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leukoc Biol 2001; 69 (2): 241-247.
  14. Данилов С.И., Назаров П.Г. Новая концепция формирования серорезистентности после лечения сифилиса. Инфекции, передаваемые половым путем, 2000; (2): 16-19.
  15. Ломоносов К.М. Иммунорегуляторные нарушения как причина серорезистентности и замедленной негативации серологических реакций при сифилисе (клинико-иммунологические аспекты). Диссертация.. д.м.н. М; 2000.
  16. Vyaz'mina E.S., Novikova S.I., Frigo N.V., Komarova V.D., Dobrotina N.A., Novikov V.V. Soderzhanie rastvorimykh form antigenov CD50 i HLA
  17. Вязьмина Е.С., Новикова С.И., Фриго Н.В., Комарова В.Д., Добротина Н.А., Новиков В.В. Содержание растворимых форм антигенов CD50 и HLA 1 класса у больных с серорезистентностью после лечения сифилиса. Вестник Нижегородского университета им. Н.И. Лобачевского 2001; 1:(3): 39-45.

Copyright (c) 2014 Volkova Y.N., Morozov S.G., Mitichkina Y.V., Grigoriyeva A.A., Yelistratova I.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies